Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances

被引：0

作者：

Lessans, Spencer ^{[1
]}

O'Connell, Katie A. ^{[2
]}

Choe, Jennifer ^{[3
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Internal Med, Nashville, TN USA

[2] Vanderbilt Univ, Med Ctr, Dept Dermatol, Nashville, TN USA

[3] Vanderbilt Univ, Dept Hematol Oncol, Med Ctr, Preston Res Bldg 790,2220 Pierce Ave, Nashville, TN 37232 USA

来源：

CURRENT ONCOLOGY REPORTS | 2024年 / 26卷 / 09期

基金：

英国科研创新办公室;

关键词：

Squamous cell carcinoma; Basal cell carcinoma; Merkel cell carcinoma; Immunotherapy; Neoadjuvant; SQUAMOUS-CELL CARCINOMA; BASAL-CELL; HEDGEHOG PATHWAY; OPEN-LABEL; PHASE-II; TRANSPLANT RECIPIENTS; INHIBITOR; PEMBROLIZUMAB; POLYOMAVIRUS; CHEMOTHERAPY;

D O I：

10.1007/s11912-024-01570-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of ReviewThis review provides an update on approved and emerging systemic therapies in the treatment of locally advanced or metastatic non-melanoma skin cancers (squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma).Recent FindingsMany studies demonstrate the effectiveness of immunotherapy for all types of non-melanoma skin cancer. For basal cell carcinoma (BCC), hedgehog inhibitors (HHI) remain first-line but with poor tolerability. Numerous clinical trials studying both neoadjuvant and adjuvant use of anti-PD-1 and anti-PD-L1 therapies in advanced NMSC are under investigation.SummaryThere is a growing number of systemic therapies available to treat non-melanoma skin cancers. The advent of immunotherapy has revolutionized the field and greatly improved survival compared to historical survival rates with cytotoxic chemotherapy.

引用

页码：1120 / 1133

页数：14

共 112 条

[51]

Kartos Therapeutics Inc, 2023, PHASE 1B2 OPEN LABEL

[52] Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial [J].

Kaufman, Howard L. ;

Russell, Jeffery ;

Hamid, Omid ;

Bhatia, Shailender ;

Terheyden, Patrick ;

D'Angelo, Sandra P. ;

Shih, Kent C. ;

Lebbe, Celeste ;

Linette, Gerald P. ;

Milella, Michele ;

Brownell, Isaac ;

Lewis, Karl D. ;

Lorch, Jochen H. ;

Chin, Kevin ;

Mahnke, Lisa ;

von Heydebreck, Anja ;

Cuillerot, Jean-Marie ;

Nghiem, Paul .

LANCET ONCOLOGY, 2016, 17 (10) :1374-1385

[53] Histogenesis of Merkel Cell Carcinoma: A Comprehensive Review [J].

Kervarrec, Thibault ;

Samimi, Mahtab ;

Guyetant, Serge ;

Sarma, Bhavishya ;

Cheret, Jeremy ;

Blanchard, Emmanuelle ;

Berthon, Patricia ;

Schrama, David ;

Houben, Roland ;

Touze, Antoine .

FRONTIERS IN ONCOLOGY, 2019, 9

[54] Durable remission after rechallenge with ipilimumab and nivolumab in metastatic Merkel cell carcinoma refractory to avelumab: Any role for sequential immunotherapy? [J].

Khaddour, Karam ;

Rosman, Ilana S. ;

Dehdashti, Farrokh ;

Ansstas, George .

JOURNAL OF DERMATOLOGY, 2021, 48 (02) :E80-E81

[55] Ultraviolet radiation-induced non-melanoma skin cancer: Regulation of DNA damage repair and inflammation [J].

Kim, InYoung ;

He, Yu-Ying .

GENES & DISEASES, 2014, 1 (02) :188-198

[56] Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth [J].

Kim, James ;

Tang, Jean Y. ;

Gong, Ruoyu ;

Kim, Jynho ;

Lee, John J. ;

Clemons, Karl V. ;

Chong, Curtis R. ;

Chang, Kris S. ;

Fereshteh, Mark ;

Gardner, Dale ;

Reya, Tannishtha ;

Liu, Jun O. ;

Epstein, Ervin H. ;

Stevens, David A. ;

Beachy, Philip A. .

CANCER CELL, 2010, 17 (04) :388-399

[57] Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma [J].

Lacouture, Mario E. ;

Dreno, Brigitte ;

Ascierto, Paolo Antonio ;

Dummer, Reinhard ;

Basset-Seguin, Nicole ;

Fife, Kate ;

Ernst, Scott ;

Licitra, Lisa ;

Neves, Rogerio I. ;

Peris, Ketty ;

Puig, Susana ;

Sokolof, Jonas ;

Sekulic, Aleksandar ;

Hauschild, Axel ;

Kunstfeld, Rainer .

ONCOLOGIST, 2016, 21 (10) :1218-1229

[58] Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies [J].

Lang, R. ;

Welponer, T. ;

Richtig, E. ;

Wolf, I. ;

Hoeller, C. ;

Hafner, C. ;

Nguyen, V. A. ;

Kofler, J. ;

Barta, M. ;

Koelblinger, P. ;

Hitzl, W. ;

Emberger, M. ;

Laimer, M. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, :1799-1810

[59]

Lear John T, 2021, Oncotarget, V12, P2531, DOI 10.18632/oncotarget.28145

[60] Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study [J].

Li, C. ;

Zhu, D. ;

Fan, Z. ;

Chen, Y. ;

Li, Y. ;

Ji, M. ;

Duan, P. ;

Su, J. ;

Yang, J. ;

Tang, Y. ;

Zhang, M. ;

Wang, S. ;

Yu, G. ;

Huang, Y. ;

Chen, R. ;

Hu, X. ;

Wang, L. ;

Wang, Q. ;

Zhu, J. .

ANNALS OF ONCOLOGY, 2023, 34 :S1500-S1500

← 1 2 3 4 5 6 7 8 9 10 →